146 related articles for article (PubMed ID: 23551178)
1. Immunohistochemical detection of sphingosine-1-phosphate receptor 1 and 5 in human multiple sclerosis lesions.
Brana C; Frossard MJ; Pescini Gobert R; Martinier N; Boschert U; Seabrook TJ
Neuropathol Appl Neurobiol; 2014 Aug; 40(5):564-78. PubMed ID: 23551178
[TBL] [Abstract][Full Text] [Related]
2. Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions.
Van Doorn R; Van Horssen J; Verzijl D; Witte M; Ronken E; Van Het Hof B; Lakeman K; Dijkstra CD; Van Der Valk P; Reijerkerk A; Alewijnse AE; Peters SL; De Vries HE
Glia; 2010 Sep; 58(12):1465-76. PubMed ID: 20648639
[TBL] [Abstract][Full Text] [Related]
3. Cellular distribution of glucose and monocarboxylate transporters in human brain white matter and multiple sclerosis lesions.
Nijland PG; Michailidou I; Witte ME; Mizee MR; van der Pol SM; van Het Hof B; Reijerkerk A; Pellerin L; van der Valk P; de Vries HE; van Horssen J
Glia; 2014 Jul; 62(7):1125-41. PubMed ID: 24692237
[TBL] [Abstract][Full Text] [Related]
4. Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide.
Colombo E; Di Dario M; Capitolo E; Chaabane L; Newcombe J; Martino G; Farina C
Ann Neurol; 2014 Sep; 76(3):325-37. PubMed ID: 25043204
[TBL] [Abstract][Full Text] [Related]
5. Sphingosine 1-phosphate signaling at the blood-brain barrier.
Prager B; Spampinato SF; Ransohoff RM
Trends Mol Med; 2015 Jun; 21(6):354-63. PubMed ID: 25939882
[TBL] [Abstract][Full Text] [Related]
6. Deconstructing the Pharmacological Contribution of Sphingosine-1 Phosphate Receptors to Mouse Models of Multiple Sclerosis Using the Species Selectivity of Ozanimod, a Dual Modulator of Human Sphingosine 1-Phosphate Receptor Subtypes 1 and 5.
Selkirk JV; Dines KC; Yan YG; Ching N; Dalvie D; Biswas S; Bortolato A; Schkeryantz JM; Lopez C; Ruiz I; Hargreaves R
J Pharmacol Exp Ther; 2021 Dec; 379(3):386-399. PubMed ID: 34535564
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of distinct galectins in multiple sclerosis lesions.
Stancic M; van Horssen J; Thijssen VL; Gabius HJ; van der Valk P; Hoekstra D; Baron W
Neuropathol Appl Neurobiol; 2011 Oct; 37(6):654-71. PubMed ID: 21501208
[TBL] [Abstract][Full Text] [Related]
8. Small heat shock proteins are induced during multiple sclerosis lesion development in white but not grey matter.
Peferoen LA; Gerritsen WH; Breur M; Ummenthum KM; Peferoen-Baert RM; van der Valk P; van Noort JM; Amor S
Acta Neuropathol Commun; 2015 Dec; 3():87. PubMed ID: 26694816
[TBL] [Abstract][Full Text] [Related]
9. Sphingosine signalling regulates decidual NK cell angiogenic phenotype and trophoblast migration.
Zhang J; Dunk CE; Lye SJ
Hum Reprod; 2013 Nov; 28(11):3026-37. PubMed ID: 24001716
[TBL] [Abstract][Full Text] [Related]
10. Sphingosine-1-Phosphate Receptors in the Central Nervous and Immune Systems.
Healy LM; Antel JP
Curr Drug Targets; 2016; 17(16):1841-1850. PubMed ID: 26424391
[TBL] [Abstract][Full Text] [Related]
11. Heat shock proteins are differentially expressed in brain and spinal cord: implications for multiple sclerosis.
Gorter RP; Nutma E; Jahrei MC; de Jonge JC; Quinlan RA; van der Valk P; van Noort JM; Baron W; Amor S
Clin Exp Immunol; 2018 Nov; 194(2):137-152. PubMed ID: 30014472
[TBL] [Abstract][Full Text] [Related]
12. Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes.
van Doorn R; Nijland PG; Dekker N; Witte ME; Lopes-Pinheiro MA; van het Hof B; Kooij G; Reijerkerk A; Dijkstra C; van van der Valk P; van Horssen J; de Vries HE
Acta Neuropathol; 2012 Sep; 124(3):397-410. PubMed ID: 22810490
[TBL] [Abstract][Full Text] [Related]
13. Quantitative Analysis of S1PR1 Expression in the Postmortem Multiple Sclerosis Central Nervous System.
Jiang H; Zhou C; Qiu L; Gropler RJ; Brier MR; Wu GF; Cross AH; Perlmutter JS; Benzinger TLS; Tu Z
ACS Chem Neurosci; 2023 Nov; 14(22):4039-4050. PubMed ID: 37882753
[TBL] [Abstract][Full Text] [Related]
14. The role of sphingosine-1-phosphate receptor modulators in the prevention of transplant rejection and autoimmune diseases.
Japtok L; Kleuser B
Curr Opin Investig Drugs; 2009 Nov; 10(11):1183-94. PubMed ID: 19876786
[TBL] [Abstract][Full Text] [Related]
15. Differential loss of KIR4.1 immunoreactivity in multiple sclerosis lesions.
Schirmer L; Srivastava R; Kalluri SR; Böttinger S; Herwerth M; Carassiti D; Srivastava B; Gempt J; Schlegel J; Kuhlmann T; Korn T; Reynolds R; Hemmer B
Ann Neurol; 2014 Jun; 75(6):810-28. PubMed ID: 24777949
[TBL] [Abstract][Full Text] [Related]
16. Sphingosine-1-phosphate receptor therapies: Advances in clinical trials for CNS-related diseases.
O'Sullivan S; Dev KK
Neuropharmacology; 2017 Feb; 113(Pt B):597-607. PubMed ID: 27825807
[TBL] [Abstract][Full Text] [Related]
17. Contribution of astrocyte-derived IL-15 to CD8 T cell effector functions in multiple sclerosis.
Saikali P; Antel JP; Pittet CL; Newcombe J; Arbour N
J Immunol; 2010 Nov; 185(10):5693-703. PubMed ID: 20926794
[TBL] [Abstract][Full Text] [Related]
18. Regulation of microglial TMEM119 and P2RY12 immunoreactivity in multiple sclerosis white and grey matter lesions is dependent on their inflammatory environment.
van Wageningen TA; Vlaar E; Kooij G; Jongenelen CAM; Geurts JJG; van Dam AM
Acta Neuropathol Commun; 2019 Dec; 7(1):206. PubMed ID: 31829283
[TBL] [Abstract][Full Text] [Related]
19. Enhanced GABAergic Immunoreactivity in Hippocampal Neurons and Astroglia of Multiple Sclerosis Patients.
Kiljan S; Prins M; Baselmans BM; Bol JGJM; Schenk GJ; van Dam AM
J Neuropathol Exp Neurol; 2019 Jun; 78(6):480-491. PubMed ID: 31100147
[TBL] [Abstract][Full Text] [Related]
20. High field (9.4 Tesla) magnetic resonance imaging of cortical grey matter lesions in multiple sclerosis.
Schmierer K; Parkes HG; So PW; An SF; Brandner S; Ordidge RJ; Yousry TA; Miller DH
Brain; 2010 Mar; 133(Pt 3):858-67. PubMed ID: 20123726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
